TheraCryf Plc Hosts Ox-1 Investor Presentation
Why we think this is neutral
This RNS announcement does not contain any of the mandatory news types specified, such as contract news, order news, trading update, financing, funding, annual results, asset sale/disposal, flow testing, licence news, or delisting. Therefore, the sentiment is assessed as neutral.
Key Points
- TheraCryf plc to host Ox-1 investor presentation
- Presentation to be led by CBO Dr Helen Kuhlman and consultant Dr Fraser Murray
- Presentation open to existing and potential shareholders via Investor Meet Company platform
Summary
The clinical stage therapeutics company is hosting an investor presentation on its Ox-1 addiction programme.
TheraCryf plc, the clinical stage drug development company focussing on neuropsychiatry and oncology, will be hosting a webinar for investors to provide an in-depth look at the Ox-1 addiction programme. The session will be led by the company's CBO, Dr Helen Kuhlman, and neuroscientist and consultant, Dr Fraser Murray.
Key Dates
11 June 2025
Ox-1 Investor Presentation
GENERAL UPDATE